| 產(chǎn)品編號 | BIO1020SM |
| 英文名稱 | Anti-CD19 & CD3 Reference Antibody (Blinatumomab Biosimilar) |
| 別 名 | Angiopoietin 2 & VEGF; Blinatumomab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應 | Human |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 54.05kDa |
| 性 狀 | Lyophilized |
| 亞 型 | ScFv-ScFv |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Blinatumomab with Jurkat cells, then with the addition of hu-CD19-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.
As shown in fig, Blinatumomab was able to activate the NF-AT signaling pathway.
Blinatumomab bound to CD19 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP ) , and read OD450. As shown in fig, Blinatumomab bound to in human CD19-His, and the EC50 was 0.370 nM.
The purity of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 98.26%, determined by SEC-HPLC.
Anti-CD19 & CD3 Reference Antibody (Blinatumomab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 53.81 kDa.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
